| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.5 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.029 | 0.6 |